Medication Management in End-Stage Renal Disease

Pain Management

• Opioids without active metabolites, such as methadone, buprenorphine, or fentanyl, are the preferred choice for patients with renal dysfunction, according to the American Heart Association 1, 2, 3.
• Fentanyl and buprenorphine (transdermal or intravenous) are the safest opioids in chronic kidney disease stages 4 or 5 (eGFR <30 mL/min), as recommended by the European Society for Medical Oncology 4.
• Low-dose oral opioids are generally well tolerated and safe, with immediate-release formulations preferred initially for intermittent use, as suggested by the American College of Cardiology 1, 5.
• Meperidine, codeine, and morphine must be avoided due to active metabolites that accumulate in renal insufficiency (GFR <30 mL/min/1.73 m²), according to the Mayo Clinic 6.
• Tramadol and tapentadol are not recommended in renal insufficiency (GFR <30 mL/min/1.73 m²) and ESRD, as stated by the Mayo Clinic 6.
• Acetaminophen is widely used as initial therapy for musculoskeletal or inflammatory pain, though doses of 4 g daily may increase systolic blood pressure in hypertensive patients, as noted by the American Heart Association 1, 5, 3.
• Topical agents, such as lidocaine, diclofenac, and capsaicin, are safe alternatives, as recommended by the American College of Cardiology 1, 5, 3.
• NSAIDs must be avoided due to cardiovascular toxicity, renal toxicity, increased bleeding risk, sodium/water retention, and increased heart failure hospitalization risk, as warned by the American Heart Association 1, 5, 2, 3.
• Gabapentin and pregabalin are typically not recommended despite requiring renal dose adjustment, due to fluid retention, weight gain, and heart failure exacerbation risk, as stated by the American College of Cardiology 1, 5, 2, 3.

Psychiatric Medications

• SSRIs, particularly sertraline, are safe in ESRD and are the preferred agent due to extensive study in cardiovascular disease and lower QTc prolongation risk, as recommended by the American Heart Association 1, 5, 2, 3.
• Mirtazapine is safe with additional benefits including appetite stimulation and sleep promotion, as noted by the American College of Cardiology 1, 5, 2, 3.
• Monoamine oxidase inhibitors and tricyclic antidepressants should be avoided due to significant cardiovascular side effects, as warned by the American Heart Association 1, 5, 2, 3.

Antimicrobial Agents

• Ciprofloxacin requires dose reduction: 250-500 mg q12h for creatinine clearance >50 mL/min; 250-500 mg q18h for 10-50 mL/min; 250-500 mg q24h for <10 mL/min, as recommended by the Infectious Diseases Society of America 7.
• Levofloxacin: 500 mg loading dose, then 250 mg q24h for creatinine clearance 50-80 mL/min; 250 mg q48h for <50 mL/min, as suggested by the Infectious Diseases Society of America 7.
• Trimethoprim-sulfamethoxazole: reduce to half dose for creatinine clearance 15-30 mL/min; half dose or use alternative for <15 mL/min, as recommended by the Infectious Diseases Society of America 7.
• Fluconazole requires 50% dose reduction for creatinine clearance <50 mL/min, as noted by the Infectious Diseases Society of America 7.
• Glecaprevir/pibrentasvir is the treatment of choice for chronic hepatitis C with stage 4 or 5 CKD, including hemodialysis patients, with 99% SVR rates, as recommended by the European Association for the Study of the Liver 8.
• Sofosbuvir-based regimens can be used when no other relevant treatment options are available, though sofosbuvir metabolite exposure increases 20-fold in ESRD, as noted by the European Association for the Study of the Liver 8.

Critical Pitfalls

• Always check for active metabolites when prescribing opioids—accumulation causes respiratory depression, falls, and confusion, as warned by the American Heart Association 1, 5, 2.
• Avoid combining sedating medications with antihypertensives and diuretics due to amplified fall risk and orthostatic hypotension, as recommended by the American College of Cardiology 1, 5, 2.

Medication Safety in End-Stage Renal Disease (ESRD)

Contraindicated and High-Risk Medications

• The American Journal of Kidney Diseases recommends avoiding Ammonium chloride entirely in ESRD due to severe risk of metabolic acidosis, as patients with GFR <30 mL/min cannot adequately excrete the acid load, leading to life-threatening acidemia 9, 10
• The National Kidney Foundation, as reported in Nature Reviews Nephrology, advises against using Acebrophylline in ESRD unless no alternatives exist, due to insufficient safety data and potential for altered pharmacodynamics in renal insufficiency 11

Safe Medications with Caution

• The American Journal of Kidney Diseases suggests that medications like Bromhexine and Ambroxol should be used with caution in ESRD, as they lack robust pharmacokinetic data in ESRD patients, despite being primarily hepatically metabolized 12

Medication Management

• The American Journal of Kidney Diseases recommends verifying current medication lists at every care transition to prevent medication discrepancies, a leading cause of morbidity in dialysis patients, and to bring medication bottles to all appointments and hospitalizations to ensure accurate reconciliation 12
• The National Kidney Foundation, as reported in Nature Reviews Nephrology and the American Journal of Kidney Diseases, advises withdrawing potentially nephrotoxic or interacting agents when adding new medications to ESRD patients, who typically take multiple medications that can interact through altered protein binding, competition for tubular secretion, or additive toxicities 11, 9, 12